Dapagliflozin Preventing a progression of Cardio renal metabolic complications | IDEC2021

Dapagliflozin Preventing a progression of Cardio renal metabolic complications | IDEC2021

Dapagliflozin : Preventing a progression of Cardio - renal - metabolic complicationsПодробнее

Dapagliflozin : Preventing a progression of Cardio - renal - metabolic complications

State of the Art: Diabetes Management with Respect to CVD and CKD in 2018Подробнее

State of the Art: Diabetes Management with Respect to CVD and CKD in 2018

SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?Подробнее

SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?

SGLT2i Cardio-renal benefits & beyond - Focus on DapagliflozinПодробнее

SGLT2i Cardio-renal benefits & beyond - Focus on Dapagliflozin

Evolution From Anti diabetic To Cardio renal Protection | IDEC 2021Подробнее

Evolution From Anti diabetic To Cardio renal Protection | IDEC 2021

Cardiorenal Complications in Diabetes: Challenges, Prevention and management strategiesПодробнее

Cardiorenal Complications in Diabetes: Challenges, Prevention and management strategies

SGLT2i Cardio-renal benefits & beyond - Focus on DapagliflozinПодробнее

SGLT2i Cardio-renal benefits & beyond - Focus on Dapagliflozin

CARDIO-RENAL METABOLIC AXIS / Prof Amr EL MeligiПодробнее

CARDIO-RENAL METABOLIC AXIS / Prof Amr EL Meligi

Cardio Kidney Metabolic Disease: Spotlight on Kidney FunctionПодробнее

Cardio Kidney Metabolic Disease: Spotlight on Kidney Function

SGLT2 and Cardiovascular Outcome Trials current perspectives and future potential | IDEC2021Подробнее

SGLT2 and Cardiovascular Outcome Trials current perspectives and future potential | IDEC2021

Stage 1 3 Diabetic Kidney Disease Assessment And Management | IDEC 2021Подробнее

Stage 1 3 Diabetic Kidney Disease Assessment And Management | IDEC 2021

Ep 18: Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitusПодробнее

Ep 18: Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus

Further research studies of DapagliflozinПодробнее

Further research studies of Dapagliflozin

How does Dapagliflozin work? Understanding SGLT2 inhibitors.Подробнее

How does Dapagliflozin work? Understanding SGLT2 inhibitors.

SGLT2 Inhibitors in Type 2 DM: A Cardiorenal "Game-Changer"Подробнее

SGLT2 Inhibitors in Type 2 DM: A Cardiorenal 'Game-Changer'

HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HFПодробнее

HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF

"Cardio-renal Risk Reduction Across the Spectrum of Type 2 DM" presented by Anip BansalПодробнее

'Cardio-renal Risk Reduction Across the Spectrum of Type 2 DM' presented by Anip Bansal

SGLT2 Inhibitors: A Future in Cardiorenal Metabolic SyndromeПодробнее

SGLT2 Inhibitors: A Future in Cardiorenal Metabolic Syndrome